RU2014148877A - Methods for influencing BRCA1 gene expression - Google Patents
Methods for influencing BRCA1 gene expression Download PDFInfo
- Publication number
- RU2014148877A RU2014148877A RU2014148877A RU2014148877A RU2014148877A RU 2014148877 A RU2014148877 A RU 2014148877A RU 2014148877 A RU2014148877 A RU 2014148877A RU 2014148877 A RU2014148877 A RU 2014148877A RU 2014148877 A RU2014148877 A RU 2014148877A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- brca1 gene
- influencing
- gene
- antisense oligonucleotide
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ воздействия на экспрессию гена BRCA1 в клетках пациента, включающий: приведение в контакт указанных клеток с одной или несколькими миРНК, специфичными для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности указанного гена.2. Способ по п. 1, где экспрессию понижают.3. Композиция, содержащая одну или более миРНК, специфичных для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности гена BRCA1.4. Способ лечения заболевания, связанного с геном BRCA1, включающий введение пациенту эффективной дозы одной или нескольких миРНК, специфичных для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности гена BRCA1.1. A method of influencing the expression of the BRCA1 gene in a patient’s cells, comprising: contacting said cells with one or more siRNAs specific for an antisense oligonucleotide, with a sequence of at least 70% identical sequence to the specified gene. The method of claim 1, wherein the expression is reduced. A composition comprising one or more siRNAs specific for an antisense oligonucleotide, with a sequence of at least 70% identical sequence to the BRCA1.4 gene. A method of treating a disease associated with the BRCA1 gene, comprising administering to the patient an effective dose of one or more siRNAs specific for the antisense oligonucleotide, with a sequence of at least 70% identical sequence to the BRCA1 gene.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014148877A RU2014148877A (en) | 2014-12-04 | 2014-12-04 | Methods for influencing BRCA1 gene expression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014148877A RU2014148877A (en) | 2014-12-04 | 2014-12-04 | Methods for influencing BRCA1 gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014148877A true RU2014148877A (en) | 2016-06-27 |
Family
ID=56195376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014148877A RU2014148877A (en) | 2014-12-04 | 2014-12-04 | Methods for influencing BRCA1 gene expression |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2014148877A (en) |
-
2014
- 2014-12-04 RU RU2014148877A patent/RU2014148877A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
| BR112017004349A2 (en) | globin gene therapy for treatment of hemoglobinopathies | |
| MX363243B (en) | Compositions and methods for treating cancer. | |
| EA201791624A1 (en) | COMPOUNDS TO IMPROVE SPLISING of mRNA | |
| MX2020011415A (en) | Methods of using zscan4 for rejuvenating human cells. | |
| EA201591543A1 (en) | COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS | |
| TR201818825T4 (en) | LNCRNAS FOR THE TREATMENT AND DIAGNOSIS OF CARDIAC HYPERTROPHY | |
| MX2017008462A (en) | Methods of using smad7 antisense oligonucleotides. | |
| EA201790563A8 (en) | APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY | |
| MX2015012444A (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens. | |
| BR112018008931A8 (en) | "compounds for treating hypoproliferative disorders" | |
| UY35438A (en) | PROCEDURE TO PREPARE INHIBITORS OF GLUCOSILCERAMIDE SINTASA. | |
| MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
| RU2014148877A (en) | Methods for influencing BRCA1 gene expression | |
| RU2014145911A (en) | Methods for influencing BRCA2 gene expression | |
| BR112017011513A2 (en) | treatment of eye conditions using progenitor cells | |
| RU2014148258A (en) | Methods for influencing ADA gene expression | |
| RU2014148879A (en) | Methods for influencing PRP gene expression | |
| RU2014145910A (en) | Methods for influencing APOE gene expression | |
| RU2014142756A (en) | Methods for influencing D4DR gene expression | |
| RU2014144701A (en) | Methods for influencing TER1 gene expression | |
| RU2014142755A (en) | Methods for influencing CYP17 gene expression | |
| ES2571441A1 (en) | Use of molecules that reduce the levels of lipocalin-2 for the manufacture of a medicine for the treatment of abdominal aortic aneurysm (aaa) (Machine-translation by Google Translate, not legally binding) | |
| RU2014144093A (en) | Methods for influencing CRE gene expression | |
| TR201903234T4 (en) | Pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease. |